165 related articles for article (PubMed ID: 23277241)
1. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Warren KR; Buchanan RW; Feldman S; Conley RR; Linthicum J; Ball MP; Liu F; McMahon RP; Gorelick DA; Huestis MA; Kelly DL
J Clin Psychopharmacol; 2013 Feb; 33(1):118-20. PubMed ID: 23277241
[No Abstract] [Full Text] [Related]
2. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Kelly DL; Gorelick DA; Conley RR; Boggs DL; Linthicum J; Liu F; Feldman S; Ball MP; Wehring HJ; McMahon RP; Huestis MA; Heishman SJ; Warren KR; Buchanan RW
J Clin Psychopharmacol; 2011 Feb; 31(1):86-91. PubMed ID: 21192149
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
4. Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats.
Scherma M; Fattore L; Satta V; Businco F; Pigliacampo B; Goldberg SR; Dessi C; Fratta W; Fadda P
Br J Pharmacol; 2013 Jun; 169(4):820-33. PubMed ID: 23072421
[TBL] [Abstract][Full Text] [Related]
5. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
Tallett AJ; Blundell JE; Rodgers JR
Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
Maccarrone M; Wang H; Dey SK
Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
[No Abstract] [Full Text] [Related]
9. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
10. Rehabilitating rimonabant.
Luft FC
J Mol Med (Berl); 2013 Jul; 91(7):777-9. PubMed ID: 23591956
[No Abstract] [Full Text] [Related]
11. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
12. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.
Motaghedi R; Lipman EG; Hogg JE; Christos PJ; Vogiatzi MG; Angulo MA
Eur J Med Genet; 2011; 54(1):14-8. PubMed ID: 20965292
[TBL] [Abstract][Full Text] [Related]
13. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
14. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
McLaughlin PJ
Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
16. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
17. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid type 1 receptor antagonists for smoking cessation.
Cahill K; Ussher MH
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
[TBL] [Abstract][Full Text] [Related]
19. [New drugs; rimonabant].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
Carai MA; Colombo G; Maccioni P; Gessa GL
CNS Drug Rev; 2006; 12(2):91-9. PubMed ID: 16958983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
